Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease.

Autor: den Haan J; Department of Neurology, Amsterdam Neuroscience, Alzheimer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Mailbox 7057, 1007, MB, Amsterdam, The Netherlands. j.denhaan1@vumc.nl., Csinscik L; Centre for Experimental Medicine, Queen's University, Belfast, UK.; Institute of Ophthalmology UCL, London, UK., Parker T; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK., Paterson RW; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK., Slattery CF; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK., Foulkes A; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK., Bouwman FH; Department of Neurology, Amsterdam Neuroscience, Alzheimer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Mailbox 7057, 1007, MB, Amsterdam, The Netherlands., Verbraak FD; Department of Ophthalmology, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands., Scheltens P; Department of Neurology, Amsterdam Neuroscience, Alzheimer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Mailbox 7057, 1007, MB, Amsterdam, The Netherlands., Peto T; Centre for Experimental Medicine, Queen's University, Belfast, UK.; NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL, London, UK., Lengyel I; Centre for Experimental Medicine, Queen's University, Belfast, UK.; Institute of Ophthalmology UCL, London, UK., Schott JM; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK., Crutch SJ; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK., Shakespeare TJ; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK., Yong KXX; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Jazyk: angličtina
Zdroj: Alzheimer's research & therapy [Alzheimers Res Ther] 2019 Jul 18; Vol. 11 (1), pp. 62. Date of Electronic Publication: 2019 Jul 18.
DOI: 10.1186/s13195-019-0516-x
Abstrakt: Background: Retinal thickness can be measured non-invasively with optical coherence tomography (OCT) and may offer compelling potential as a biomarker for Alzheimer's disease (AD). Retinal thinning is hypothesized to be a result of retrograde atrophy and/or parallel neurodegenerative processes. Changes in the visual pathway are of particular interest in posterior cortical atrophy (PCA), the most common atypical AD phenotype predominantly affecting the parietal-occipital cortices. We therefore evaluated retinal thickness as non-invasive biomarker of neurodegeneration in well-characterized participants with posterior cortical atrophy (PCA) and typical Alzheimer's disease (tAD).
Methods: Retinal thickness measures were acquired from 48 patient participants (N = 25 PCA; N = 23 tAD) fulfilling consensus diagnostic criteria and 70 age-matched controls. Participants were recruited between 2014 and 2016. All participants underwent optical coherence tomography (OCT) imaging, including measurement of peripapillary retinal nerve fiber layer (pRNFL) thickness and total macular thickness (mRT). Participants did not show evidence of any significant ophthalmological conditions. Subgroup analyses were performed in participants with available MRI and CSF measures, providing evidence of neurodegeneration and underlying AD pathology respectively.
Results: There was no evidence of overall between-group differences in pRNFL thickness (mean PCA 98.7 ± 12.2; tAD 99.9 ± 8.7; controls 99.6 ± 10.0 μm, one-way analysis of variance (ANOVA) p = 0.92) or total mRT (mean PCA 266.9 ± 16.3; tAD 267.8 ± 13.6; controls 269.3 ± 13.6 μm, one-way ANOVA p = 0.75). Similarly, subgroup analysis with MRI biomarkers (PCA = 18, tAD = 17, controls = 31) showing neurodegeneration, and CSF biomarkers (PCA = 18, tAD = 14, controls = 13) supporting underlying AD pathology did not provide evidence of overall between-group differences in pRNFL or mRT measures (all p > 0.3).
Conclusions: Retinal thickness did not discriminate tAD and PCA from controls or from one another despite unequivocal differences on standard clinical, neuro-imaging and CSF measures. Findings from this well-characterized sample, including cases with PCA, do not support the hypothesis that retinal neurodegeneration, measured using conventional OCT, is a useful biomarker for AD or PCA.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje